DMAPT

CAT: 0804-HY-16172-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-16172-01Size:5 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
DMAPT (Dimethylamino Parthenolide), an analogue of Parthenolide (PTL), is an oral active NF-κB inhibitor, with a LD50 of 1.7 μM for cell population in AML cells. Has potential anti-cancer and anti-metastatic effect[1].
CAS Number
[791595-09-0]
Product Name Alternative
Dimethylamino Parthenolide
UNSPSC
12352005
Target
NF-κB
Type
Reference compound
Related Pathways
NF-κB
Applications
Neuroscience-Neuromodulation
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/DMAPT.html
Concentration
10mM
Purity
98.0
Solubility
DMSO : 125 mg/mL (ultrasonic) |H2O : 1.1 mg/mL (ultrasonic; warming; heat to 40°C)
Smiles
C[C@]12[C@@](O2)([H])[C@]3([H])[C@](CC/C(C)=C\CC1)([H])[C@@H](C(O3)=O)CN(C)C
Molecular Formula
C17H27NO3
Molecular Weight
293.40
References & Citations
[1]Neelakantan S, et al. Aminoparthenolides as novel anti-leukemic agents: Discovery of the NF-kappaB inhibitor, DMAPT (LC-1) . Bioorg Med Chem Lett. 2009 Aug 1;19 (15) :4346-9.|[2]Mendonca MS, et al. DMAPT inhibits NF-κB activity and increases sensitivity of prostate cancer cells to X-rays in vitro and in tumor xenografts in vivo. Free Radic Biol Med. 2017 Nov;112:318-326.|[3]Morel KL, et al. Chronic low dose ethanol induces an aggressive metastatic phenotype in TRAMP mice, which is counteracted by parthenolide. Clin Exp Metastasis. 2018 Oct;35 (7) :649-661.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Popular Products